Bitterman Kevin sold $4.4M of IRON (indirect holdings)
Bitterman Kevin sold 54,496 indirectly-held shares of Disc Medicine, Inc. (IRON) at an average of $80.15 ($79.95–$80.98, $4.37M total) across 12 trades over 2026-09-01 to 2026-09-03 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
Insider sales are closely watched; a director's sale of $4.4M is notable for Disc Medicine.
Market read
The filing provides fresh, material information that could influence short‑term trading decisions on IRON.
What to watch
The director retains a non‑trivial stake (13,445 shares) and may still be aligned with company performance.
Background
SEC Form 4 filing discloses insider transactions for public companies.
Ticker impact
Director Kevin Bitterman sold 54,496 shares for $4.37M via a 10b5‑1 plan, reducing his stake to 13,445 shares.
Potential modest downside pressure over the next few days.
A $4.4M sale by a director is material for a mid‑cap biotech; the 10b5‑1 plan suggests pre‑planned execution, but the size relative to float can still affect sentiment.
Market effects
May raise concerns for other biotech stocks with recent insider sales.
Limited to U.S. biotech sector; no broader regional effect.
Low global relevance beyond Disc Medicine investors.
Counterpoint
The sale could be routine execution of a pre‑arranged plan, not a negative signal.
Key entities
- CompanyDisc Medicine, Inc.
Biotech firm listed on NASDAQ under ticker IRON.
- IndividualKevin Bitterman
Director of Disc Medicine who executed the sale.